← FDA DRUG APPROVALS

FDA ANDA · ANDA078807

METOCLOPRAMIDE

Sponsor: IPCA LABS LTD

APPLICATION
ANDA078807
TYPE
ANDA
ORIGINAL APPROVAL
2008-06-12
LATEST ACTION
2025-08-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

METOCLOPRAMIDE HYDROCHLORIDEPrescription
METOCLOPRAMIDE HYDROCHLORIDE EQ 10MG BASE · TABLET · ORAL
METOCLOPRAMIDE HYDROCHLORIDEPrescription
METOCLOPRAMIDE HYDROCHLORIDE EQ 5MG BASE · TABLET · ORAL

Approval history

2025-08-01Labeling · Supplement 14 · standardAP
2025-08-01Labeling · Supplement 13 · standardAP
2019-04-05Labeling · Supplement 10 · standardAP
2012-03-08Labeling · Supplement 8AP
2012-02-21Labeling · Supplement 6AP
2010-03-31Labeling · Supplement 3AP
2009-12-01Labeling · Supplement 2AP
2008-06-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →